 Connection
Michael Bristow to Phosphodiesterase Inhibitors
This is a "connection" page, showing publications Michael Bristow has written about Phosphodiesterase Inhibitors.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.632 |
|
|
|
-
Movsesian M, Stehlik J, Vandeput F, Bristow MR. Phosphodiesterase inhibition in heart failure. Heart Fail Rev. 2009 Dec; 14(4):255-63.
Score: 0.303
-
Lowes BD, Shakar SF, Metra M, Feldman AM, Eichhorn E, Freytag JW, Gerber MJ, Liard JF, Hartman C, Gorczynski R, Evans G, Linseman JV, Stewart J, Robertson AD, Roecker EB, Demets DL, Bristow MR. Rationale and design of the enoximone clinical trials program. J Card Fail. 2005 Dec; 11(9):659-69.
Score: 0.245
-
Lowes BD, Tsvetkova T, Eichhorn EJ, Gilbert EM, Bristow MR. Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol. Int J Cardiol. 2001 Dec; 81(2-3):141-9.
Score: 0.186
-
Shakar SF, Bristow MR. Low-level inotropic stimulation with type III phosphodiesterase inhibitors in patients with advanced symptomatic chronic heart failure receiving beta-blocking agents. Curr Cardiol Rep. 2001 May; 3(3):224-31.
Score: 0.178
-
Lowes BD, Higginbotham M, Petrovich L, DeWood MA, Greenberg MA, Rahko PS, Dec GW, LeJemtel TH, Roden RL, Schleman MM, Robertson AD, Gorczynski RJ, Bristow MR. Low-dose enoximone improves exercise capacity in chronic heart failure. Enoximone Study Group. J Am Coll Cardiol. 2000 Aug; 36(2):501-8.
Score: 0.169
-
Shakar SF, Abraham WT, Gilbert EM, Robertson AD, Lowes BD, Zisman LS, Ferguson DA, Bristow MR. Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. J Am Coll Cardiol. 1998 May; 31(6):1336-40.
Score: 0.145
-
Gilbert EM, Hershberger RE, Wiechmann RJ, Movsesian MA, Bristow MR. Pharmacologic and hemodynamic effects of combined beta-agonist stimulation and phosphodiesterase inhibition in the failing human heart. Chest. 1995 Dec; 108(6):1524-32.
Score: 0.123
-
O'Connell JB, Gilbert EM, Renlund DG, Bristow MR. Enoximone as a bridge to heart transplantation: the Utah experience. J Heart Lung Transplant. 1991 May-Jun; 10(3):477-81.
Score: 0.089
-
Bristow MR, Lee HE, Gilbert EM, Renlund DG, Hegewald MG, Hershberger RE, O'Connell JB. Use of enoximone in patients awaiting cardiac transplant. Br J Clin Pract Suppl. 1988 Dec; 64:69-72.
Score: 0.075
-
Bristow MR, Shakar SF, Linseman JV, Lowes BD. Inotropes and beta-blockers: is there a need for new guidelines? J Card Fail. 2001 Jun; 7(2 Suppl 1):8-12.
Score: 0.045
-
Lowes BD, Simon MA, Tsvetkova TO, Bristow MR. Inotropes in the beta-blocker era. Clin Cardiol. 2000 Mar; 23(3 Suppl):III11-6.
Score: 0.041
-
Focaccio A, Peeters G, Movsesian M, Roden R, Eki Y, Krall J, Bristow MR. Mechanism of action of OPC-8490 in human ventricular myocardium. Circulation. 1996 Feb 15; 93(4):817-25.
Score: 0.031
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|